Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
Public ClinicalTrials.gov record NCT01938001. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/Refractory Indolent Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This double-blind randomized, parallel group study will evaluate the efficacy and safety of lenalidomide (Revlimid, CC-5013) in combination with rituximab (MabThera/Rituxan) in patients with relapsed or refractory follicular lymphoma or marginal zone lymphoma. Patients will be randomized to receive either lenalidomide or placebo for twelve 28-day cycles in combination with rituximab. Anticipated time on study treatment is 1 year.
Study identification
- NCT ID
- NCT01938001
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 358 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 21, 2013 (Actual)
- Primary completion
- Jun 22, 2018 (Actual)
- Completion
- Jan 26, 2022 (Actual)
- Last update posted
- Feb 22, 2023
2013 – 2022
United States locations
- U.S. sites
- 35
- U.S. states
- 22
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mitchell Cancer Center, University of South Alabama | Mobile | Alabama | 36604 | — |
| Arizona Center for Cancer Care | Glendale | Arizona | 85306 | — |
| Southwest Cancer Care Medical Group | Escondido | California | 92025 | — |
| Marin Oncology Associates | Greenbrae | California | 94904-2007 | — |
| Wilshire Oncology Medical Group, Inc | La Verne | California | 91750 | — |
| North County Hematology Oncology (NCHO) - TRM, LLC. | Oceanside | California | 92056 | — |
| Hematology-Oncology Medical Group of Orange County, Inc. | Orange | California | 92868 | — |
| UC Davis Medical Center | Sacramento | California | 95817 | — |
| Central Coast Medical Oncology Corporation | Santa Maria | California | 93454 | — |
| Wellness Hematology Oncology | West Hills | California | 92056 | — |
| Cancer Center of Central Connecticut | Southington | Connecticut | 06489 | — |
| Florida Cancer Specialists North Region Sarah Cannon Research | St. Petersburg | Florida | 33705 | — |
| Illinois Cancer Care, P.C. | Peoria | Illinois | 61615 | — |
| LRG Healthcare Oncology Clinic | Laconia | Indiana | 03246 | — |
| Iowa Oncology Research Association | Des Moines | Iowa | 50309 | — |
| University of Louisville, J.G. Brown Cancer Center | Louisville | Kentucky | 40202 | — |
| Providence Cancer Institute | Southfield | Michigan | 48075 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Coborn Cancer Center at the St. Cloud Hospital | Saint Cloud | Minnesota | 56303 | — |
| NH Oncology - Hematology, PA | Hooksett | New Hampshire | 03106 | — |
| The Cancer Center at Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Hematology-Oncology Associates of Northern NJ | Morristown | New Jersey | 07962 | — |
| University of New Mexico | Albuquerque | New Mexico | 87102 | — |
| Weill Cornell Medical College | New York | New York | 10065 | — |
| SUNY Upstate Medical University | Syracuse | New York | 13210 | — |
| Wake Forest Baptist Health | Winston-Salem | North Carolina | 27157 | — |
| Oncology Hematology Care Sarah Cannon Research | Cincinnati | Ohio | 45242 | — |
| Local Institution - 028 | Portland | Oregon | 97213 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| St Francis Hospital | Greenville | South Carolina | 29607 | — |
| Spartanburg Regional Healthcare System - Gibbs Cancer Center & Research Institute | Spartanburg | South Carolina | 29303 | — |
| Sarah Cannon Research Inst | Nashville | Tennessee | 37203 | — |
| Arlington Cancer Center | Arlington | Texas | 76012 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Northwest Medical Specialties PLLC | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 125 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01938001, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 22, 2023 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01938001 live on ClinicalTrials.gov.